Slides
Page 1
First Quarter 2025 Earnings April 28, 2025
Page 2
Safe Harbor This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flo w and revenue growth and other financial results, developments relating to our customers and end-markets, plans concerning business development opportunities, acquisitions or divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. A detailed description of these risk factors can be found under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation. In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this presentation also contains non-GAAP financial measures. A reconciliation of these measures to the most directly comparable GAAP measures is included in the embedded hyperlink and is available on the “Financial Information” section of our website at www.revvity.com. 2
Page 3
Key Takeaways Innovation Transformation Performance Expanded NGS partnership with Genomics England Received FDA approval for more automated latent TB workflow Solid organic growth driven by Diagnostics & Software Strong synergy realization & Cash flow generation Leveraging strong execution and balanced portfolio to appropriately navigate dynamic macroeconomic environment A Scientific Solutions Company Helping To Solve The World's Greatest Health Challenges From Discovery To Development, and Diagnosis to Cure 3
Page 4
4 1Q25 Revenue Highlights Diagnostics Life Sciences AMERICAS APAC EU Recurring Non-recurring Segments Geographic Product Mix +MSD +MSD +LSD $0.7 B+LSD+MSD +MSD -LDD $0.7 B $0.7 B Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our website and in this hyperlink
Page 5
1Q25 Financial Results 5 REVENUE ADJUSTED OP MARGIN ADJUSTED EPS FREE CASH FLOW $665M +2% y/y 25.6% +5bps y/y $1.01 +4% y/y Organic: +4% | M&A: 0% | FX: -1% Adj. Gross Margin: 61.7% | +80bps y/y Adj. Tax Rate: 19.5% Adj. Net Interest & Other: $18M $118M Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our website and in this hyperlink YTD FCF % Adj. NI: 97%
Page 6
$340 M 1Q25 revenue LIFE SCIENCE SOLUTIONS SOFTWARE 6 Life Sciences 2% Reported: 1% | M&A: 0% | FX: -1% Organic Growth 31.1% +110bps y/y REVENUE AJUSTED OP MARGINS -LSD +DD + LSD + DD + DD - HSD - DD • +LSD growth from Pharma/Biotech, -LSD decline from Academic/Gov’t • -LSD decline in Life Science Solutions; instrument declines partially offset by solid reagent growth • +DD software growth driven by new orders, strong renewals and SaaS performance • Margin expansion yr/yr driven by mix and synergies, partially offset by investments Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our website and in this hyperlink
Page 7
7 Diagnostics • +HSD ImmunoDX globally; +LSD in China • +LSD Reproductive Health globally driven by strength in newborn • Margin decline driven by strategic investments 5% Reported: 3% | M&A: 0% | FX: -2% Organic Growth 22.8% -150 bps y/y REVENUE AJUSTED OP MARGINS $324 M 1Q25 revenue+HSD +LSD Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our website and in this hyperlink IMMUNODIAGNOSTICS REPRODUCTIVE HEALTH
Page 8
2025 Financial Guidance 8 REVENUE $2.83B - $2.87B $4.90 - $5.00 Reported: 3% to 4% Organic: 3% to 5% FX: -0.5%, M&A: 0% ADJUSTED OP. MARGIN 27.9-28.1% ADJUSTED EPS Adj. Net interest expense, other: ~$75M Adjusted tax rate: ~19% Average diluted share count: 119M
Page 9
Revvity.com